- Pharmaceutical companies
- PharmaEngine
PharmaEngine
Phone: +886 2 2515–8228
Fax: +886 2 2515–7558
E-mail: info@pharmaengine.com
Web: https://www.pharmaengine.com/
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 2 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, so far, ONIVYDE® has received marketing approval in more than 40 countries, including Taiwan, US, EU, Australia, Canada, South Korea, and Japan. PEP07, a checkpoint kinase 1 (Chk1) inhibitor, which targets the DNA Damage Response (DDR) network, is currently in the pre-clinical stage.
For detailed contact information visit location pages below.
PharmaEngine's locations around the world
Asia
Clinical Trials sponsored by PharmaEngine
-
PharmaEngineVoltooidGemetastaseerde colorectale kankerTaiwan
-
PharmaEngineVoltooid
-
PharmaEngineWervingAcute myeloïde leukemie | Lymfoom, mantelcelAustralië
-
PharmaEngineNog niet aan het wervenGeavanceerde vaste tumor | Metastatische vaste tumor
-
PharmaEngineVoltooidRefractaire vaste tumorenTaiwan
-
PharmaEngineBeëindigd
-
PharmaEngineBeëindigdHoofd-hals plaveiselcelcarcinoomTaiwan
-
PharmaEngineVoltooidPancreasneoplasmataTaiwan, Verenigde Staten
-
PharmaEngineVoltooidMaagneoplasmata | SlokdarmneoplasmataKorea, republiek van, Spanje, Taiwan, Bosnië-Herzegovina, Verenigd Koninkrijk, Kroatië